Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism AMSTERDAM, April 21, 2022 (GLOBE NEWSWIRE) -- Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces today the completion of a seed funding...